Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

U.S. officials report more severe allergic reactions to COVID-19 vaccines

Published 01/06/2021, 01:09 PM
Updated 01/06/2021, 01:10 PM
© Reuters. FILE PHOTO: Health Care workers receive the Pfizer-BioNTech COVID-19 Vaccine in Florida

By Manas Mishra and Julie Steenhuysen

(Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) said on Wednesday it is carefully monitoring allergic reactions to the coronavirus vaccines from Pfizer Inc (NYSE:PFE) and Moderna (NASDAQ:MRNA) Inc and urged individuals who had a serious reaction not to get the second dose.

In a conference call with reporters, the U.S. public health agency said allergic reactions are occurring at a rate of 11.1 per 1 million vaccinations. That compared with flu vaccines, in which such reactions occur at a rate of 1.3 per 1 million shots.

The severe reactions are still "exceedingly rare," they said, stressing the need for people to get vaccinated when the shots become available to them, given the threat of death and serious disease from the coronavirus that has already claimed more than 357,000 lives in the United States alone.

The CDC said it is monitoring allergic reaction incidents closely and plans to post weekly updates on its website.

The agency is also urging that venues that deliver the vaccine be prepared not only to recognize serious allergic reactions, known as anaphylaxis, but be trained on how to treat them and recognize when individuals need to be referred to hospitals for additional care.

CDC officials said 28 people who received the coronavirus vaccine developed by Pfizer and BioNTech had severe allergic reactions. They also noted one case of anaphylaxis, which can cause throat swelling and breathing difficulty, after an individual received Moderna's vaccine.

Officials attributed the difference largely to the fact that the Pfizer/BioNTech vaccine was authorized earlier than the Moderna shot, and said the precautions apply to both.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

A study published on Wednesday in the CDC's weekly report on death and disease looking at cases between Dec. 14 and Dec. 23, identified 21 cases of anaphylaxis after the administration of 1,893,360 doses of the Pfizer/BioNTech vaccine. Of these, 71%occurred within the first 15 minutes after vaccine administration.

Britain's medical regulator has said that anyone with a history of anaphylaxis, or severe allergic reactions to a medicine or food, should not be given the Pfizer/BioNTech vaccine.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.